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Summary 
Autoantibodies from many patients with systemic lupus erythematosus bind the Sm autoantigen 
B/B' polypeptide. The binding of serial serum specimens to the 233 overlapping octapeptides 
of Sm B/B' have  shown that  of the B/B'-derived octapeptides, PPPGMRPP and PPPGIRGP 
are early targets of the autoimmune response in some lupus patients.  Rabbits immunized with 
PPPGMRPP and PPPGIRGP develop antibodies which not only bind these octapeptides, but 
also subsequently bind many other octapeptides of Sm B/B'. Eventually, the rabbits immunized 
with  one octapeptide develop autoantibodies  that  bind other  spliceosomal proteins including 
D, 70K, A, and C. Any mechanisms that operate to maintain tolerance or anergy for the spliceo- 
some are  thus  overcome.  Features considered typical of human  systemic lupus erythematosus 
are  also  found  in  these  peptide-immunized  animals,  such  as  antinuclear  antibodies,  anti-Sm 
precipitins, anti-double-stranded DNA, thrombocytopenia, seizures,  and proteinuria.  This dis- 
ease model provides access to a mechanism for the development of humoral autoimmunity and 
may provide a basis to explain  the immunopathogenesis  of lupus in  humans. 
S 
LE is a multisystem rheumatic disorder.  Autoantibodies 
are always present though their specificities may vary con- 
siderably among patients. The anti-Sm precipitating autoan- 
tibody is useful for the diagnosis of SLE (1),  and in lupus 
patients,  as much as 20% of the entire immunoglobulin reper- 
toire may bind Sm (2). The dynamic nature of SLE humoral 
autoimmunity is demonstrated by the progression of anti- 
Sm responses to also involve the structurally associated nu- 
clear ribonucleoprotein  (nRNP) 1 autoantigen  (3). 
Proteins of the spliceosomal complex are targets of both 
the anti-Sm and anti-nRNP SLE autoimmune responses. Anti- 
nRNP antibodies are directed against the 70K, A, and C pro- 
teins, whereas the B/B' and D proteins are bound by anti-Sm 
(4). The spliceosomal proteins of the Sm and nRNP autoan- 
tigens are found in complexes with U  RNAs. Anti-nRNP 
is  specific  for the complex containing  U1  R.NA,  whereas 
anti-Sm binds complexes containing U1, U2, U4/U6, or U5 
RNA.  Why the spliceosome is a major target  of SLE au- 
toimmunity  is not known. 
A recent analysis  of SLE patient  sera which contain ma- 
ture anti-Sin and anti-nRNP precipitin responses has identified 
1  Abbreviation used in this paper: nKNP, nuclear ribonucleoprotein. 
11 antigenic regions of B/B' (5).  One of the major regions 
of reactivity is a peptide sequence,  PPPGMRPP,  which is 
repeated three times in the Sm B protein,  and PPPGIRGP 
which is closely related and present only once in Sm B. Anti- 
bodies in human SLE patient sera cross-react between these 
two octapeptides. All SLE sera tested to date with both Sm 
and nRNP precipitins  bind both octapeptides  (5). 
Rabbits  have  been  immunized  with  PPPGMRPP  or 
PPPGIRGP and,  not surprisingly,  they develop high titers 
of antibodies against these immunogens.  In addition,  these 
animals variably develop an autoimmune response against many 
different structures of the spliceosome and other findings con- 
sistent with  an autoimmune  disorder. 
Materials and Methods 
Sera.  Human SLE patients were selected on the basis of satis- 
fying  the  classification criteria for  SLE (1), having  an  anti-Sin 
precipitin, binding  to the Sm B/B' protein in Western blot, and 
having stored sera available from more than 2 yr. Other patient 
sera, control SLE patient sera (which do not bind to Sm B/B' and 
do not have an anti-Sin precipitin), and control normal sera were 
available from our stored serum collection. 
Immunizations.  PPPGMRPP and PPPGIRGP were prepared in 
quantity on a lysine backbone (MAPT~; Applied Biosystems, Foster 
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PLTALLRNLGKMTC (Ro 274), VAFSDEMVPCPVTTDMC (Ro 
413), GMTSNGFTIADPDDRGML (Ro 500), and P'I'QYPPGRG- 
TPPPV (Sm B/B' 168) were also prepared as MAP  TM peptides. Six 
different immunization experiments have been initiated in male and 
female New Zealand White rabbits upon achieving a weight of 
at least 2.72 kg (about 8 wk old) after delivery from Schachtele 
Brothers (Salisbury,  MO). 
Immunizations were performed with a number of immunogens 
including PPPGMRPP (13 rabbits, 9 male, 4 female), PPPGIRGP 
(2 male), Ro 274 (2 male), Ro 413 (2 male), Ro 480 (3 male), Ro 
500 (2 male), Sm B/B' 168 (1 male), MAP  TM backbone alone (2 
male), and Freund's adjuvant with no peptide (3 male, 1 female). 
One of two protocols were followed for all immunizations. For 
immunization schedule A on day 1, CFA was emulsified with an 
equal volume (1 ml:l ml) of PBS containing 0.5 mg ofimmunogen 
(peptide or control, as indicated) and injected subcutaneously and 
intraperitoneally. Boosting with 0.5 mg immunogen in IFA into 
the subcutaneous tissue and intraperitoneal space was done on days 
26,  53,  and 99.  The final boost (0.5 mg immunogen or control) 
was given intravenously on day 152 without  adjuvant. 
Five rabbits were immunized under immunization schedule  B 
with PPPGMRPP  (4 male) or as a Freund's Adjuvant control (1 
male) which was modified from the schedule presented above after 
initial immunization on day 1. Subcutaneous and intraperitoneal 
boosting was performed on days 8, 22, and 67. Intraveneous boosts 
were administered on days  151, 275,  and 317. 
Solid-phase  Peptide  Synthesis  and Antibody Assay.  The 1,202 pos- 
sible overlapping octapeptides of the spliceosome (Sm B/B', Sm 
D, nRNP 70K, nRNP A, and nRNP C) and the 531 octapeptides 
of 60-kD Ko were prepared using solid-phase peptide chemistry 
as described in detail for Sm B/B' and 60-kD Ro previously (5, 
7). Wash steps and incubations were carried out in sealed plastic 
containers. Other assay steps were performed by lowering the pins 
into microtiter plate wells. First,  pins were blocked with 3% low- 
fat milk in PBS for 1 h at room temperature. Pins were then in- 
cubated in 1:100 dilutions  of sera (rabbit or human) in 3% milk/PBS 
with 0.05%  Tween (PBST) overnight at 4~  in humidified and 
sealed containers.  The pin blocks were then washed four times with 
PBST for 10 min each with vigorous agitation.  Next,  each pin 
was incubated  with anti-rabbit or anti-human gamma chain-specific 
IgG raised  in a goat, affinity purified and conjugated to alkaline 
phosphatase (Jackson Immuno Research Laboratories,  West Grove, 
PA) at a 1:10,000  dilution.  Para-nitrophenyl phosphate disodium 
was used as a substrate for alkaline  phosphatase and plates were 
read at 405 nm with a microelisa reader (Dynatech, Alexandria, 
VA). Results for each plate were then standardized by comparison 
with positive control pins. The same peptide sequences  were used 
as controls for all plates and were allowed to develop to a specific 
absorbance with a known concentration of a standard control serum. 
After completion of an assay, pins were sonicated for 2 h in soni- 
cation buffer (40g SDS, 4 ml/S-ME, and 62.4g sodium phosphate 
in 4 liters)  to remove antibodies, conjugate,  and substrate.  After 
sonication,  pins were washed twice in hot water and boiled in meth- 
anol for 2 min, pins were then allowed to air dry for a minimum 
of 10 rain and were stored with desiccant or used for another assay. 
ELISAs.  Standard solid-phase assays were used to measure the 
antibody reactivity in human and rabbit sera. 1 #g of antigen (Sm, 
nRNP,  PPPGMRPP  [as a MAP  TM peptide],  or PPPGIRGP [as a 
MAP  TM peptide] was coated per well in each of 96 polystyrene wells 
in 125/zl of coating buffer (34.98  g Na2CO3,  64.46 g NaHCO3 
to 2,200 ml distilled  water, pH 9.6)  for 2 h at room temperature 
or at 4~  overnight. Wells were then washed one time with 250 
/zl of PBST (0.2 M NaH2PO4,  0.2 M Na2HPO4,  1.5 M NaC1, and 
0.05% Tween, pH 7.4) per well. Wells were blocked with 150/xl 
of 0.1% BSA in PBS per well for 2 h at room temperature. After 
washing the plates, sera (human control, SLE patient, preimmune 
rabbit, or immunized rabbit) at varying dilutions were added to 
each well and plates were allowed to incubate for 2 h at room tem- 
perature or overnight at 4~  After incubation, plates were washed 
four times with 250/~1  of PBST per well.  Next, each well was 
incubated for either 2 h at room temperature or overnight at 4~ 
with anti-human gamma chain-specific IgG (or anti-rabbit gamma 
chain-specific IgG) raised in a goat, affinity purified, and conjugated 
to alkaline phosphatase 0ackson Immuno Research Laboratories) 
at a 1:10,000 dilution.  Para-nitrophenyl phosphate disodium was 
used as a substrate for alkaline  phosphatase and plates were read 
at 405  nm with a microelisa reader. 
To assure  that the PPPGMKPP and PPPGIRGP MAP  TM pep- 
tides were binding to the dish, the assay presented above was com- 
pared with the results obtained by cross-linking to the solid phase 
with glutaraldehyde,  as described (8).  In outline, bovine IgG was 
allowed to passively absorb to the plate. Then each well was treated 
with glutaraldehyde and incubated with peptide.  This assay was 
somewhat more sensitive than was the assay presented above which 
has no bovine IgG step and allows the MAP  TM peptides to directly 
absorb to the well. The relative results produced by the two assays 
were very similar,  however. As a consequence of synthesis on a 
MAP  TM backbone, we have not,  therefore, found it necessary to 
conjugate these synthetic peptides to any carrier protein. Our ex- 
perience has shown that these MAP  TM peptides sufficiently  absorb 
to polystyrene ELISA plates and provide a sensitive and specific assay. 
Other Autoantibody Assays.  Characteristic U  RNAs were de- 
tected by immunoprecipitation following the protocol described 
by Foreman et al.  (9).  Precipitating levels of Ro, La, Sm, and/or 
nRNP autoantibodies were detected by double immunodiffusion 
(10). Rabbit and human sera were tested for antinuclear antibodies 
by a standard ANA test (INOVA Diagnostics,  Inc., San Diego, 
CA) and for autoantibodies binding to native DNA by an anti- 
nDNA test (Protrac Industries,  KerrviUe,  TX) using previously 
published protocols (11, 12). 
Western  Blot.  Affinity-purified Sm and nRNP antigens and HeLa 
cell extract were subjected to electrophoresis in 12.5% polyacryl- 
amide gels containing 1% SDS (in 0.15 M Tris HC1, pH 8.8) using 
a protocol described previously (13).  These proteins were trans- 
ferred to nitrocellulose and various concentrations (1:100 and 1:1000) 
of rabbit and human sera were reacted with the proteins to assess 
for binding  (13). 
Anti-PPPGMRPP Absorption.  The MAP  TM PPPGMRPP pep- 
tide was covalently bound to cyanogen preactivated Sepharose 4B 
by the method recommended by the manufacturer (Sigma Chem- 
ical Co., St. Louis, MO) (14, 15). 15 mg of the PPPGMRPP pep- 
tide was added per each gram of Sepharose 4B used, sufficient  to 
prepare a 2-ml column. I ml of rabbit serum was circulated through 
this column for a total of four passes at 4~  overnight and consti- 
tuted  the absorbed serum.  More than  95%  of anti-MAP~PPP - 
GMRPP reactivity was removed as measured in ELISA. 
Results 
Multiple longitudinal sera were available from two patients 
with anti-Sin precipitins.  One of these patients had precip- 
itating levels of Sm and nRNP autoantibodies from the ini- 
tial serum sample. Her precipitin specificities remained con- 
stant over an 8-yr period; however, her autoimmune response 
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Figure  1.  Development  of  an 
anti-Sm  B/B'  response  in  one 
anti-Sm and anti-nKNP precipitin 
positive patient.  Binding to 211 oc- 
tapeptides  of Sm B/B' is recorded 
as absorbance (xlO00)  at 405 nm 
relative to controls.  An example of 
the background binding found  in 
a normal human serum is presented 
in A. The anti-Sin and anti-nRNP 
precipitin positive patient shows an 
increase in the number of antigenic 
regions  over time,  as shown in B 
(4/1/86), C (7/7/87), and D (12/ 
26/88) that spans 2.5 yr. Six inter- 
vening sera were also analyzed that 
show the step-wise accumulation of 
new  specificities as  shown  above 
(data not presented). The initial four 
groups  of  octapeptides  represent 
PPPGMRPP  (  !  ),  which  is  re- 
peated three times, and PPPGIRGP 
(~). 
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Figure 2.  Development of rabbit antibody binding to 211 octapeptides of Sm B/B' in one PPPGMKPP immunized rabbit  (rabbit #463). (A) Binding 
of the preimmune serum of rabbit #463. (B-D) Binding of sera from collection dates 3, 8, and 10 wk after primary immunization. (Inset, C) Binding 
of this serum after absorption  over a PPPGMRPP peptide column. Antibodies  to the PPPGMKPP repeated peptides and the PPPGIRGP peptide have 
been  removed as indicated  (  t  ) and (  0  ), respectively. 
455  James  et al. expanded from initially being directed against 70K and Sm 
B/B' proteins to subsequently binding 70K, nRNP A, nRNP 
C, Sm B/B', and Sm D proteins. The other patient initially 
had only an anti-Sm precipitin binding Sm B/B' and Sm D 
in Western blot. She eventually developed anti-nRNP pre- 
cipitins. Her serum then also bound to 70K and nRNP C 
in Western blot. The PPPGMRPP and PPPGIKGP peptides 
were the only B/B' octapeptides found to be antigenic in the 
earliest available serum from each of these patients. The binding 
of this earliest serum from the former patient to B/B' octa- 
peptides is presented in Fig. 1 B with the maturation of the 
response  shown in Fig.  1,  C  and D. 
We immunized rabbits with PPPGMRPP or PPPGIRGP 
peptides to develop antipeptide positive control reagents. An- 
tisera were produced that bound these peptides and purified 
Sm antigen at titers exceeding 1:106. Unexpectedly,  from the 
later sera the immunizing peptide was a relatively poor in- 
hibitor of antibody binding to Sm antigen, though the im- 
munizing peptide in solution effectively inhibited binding 
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Figure 3.  Sm B/B' octapeptides  bound  by rabbits immunized  with the 
PPPGMILPP peptide on a MAP  TM  lysine7 backbone (5). (.,4) Average 
binding of 10 controls, none  of which significantly  bind any of these pep- 
tides above  background. These negative  controls include  the preimmune 
sera from the PPPGMRPP and PPPGIRGP immunized  rabbits as well 
as other rabbits immunized with CEYRKKMDI (Ro 480), I.QEM- 
PLTALLRNLGKMTC (Ro 274), VAFSDEMVPCPVTTDMC  (Ro 413), 
and GMTSNGFTIADPDDRGML (Ro 500) derived  from  the 60-kD Ro 
sequence or with Freund's adjuvant alone. The sera from eight rabbits 
immunized  with PPPGMRPP which have been immunized  with protocol 
A and followed  for at least 160 d are presented  as an average  in C, whereas 
D is the average  binding of 14 human SLE sera with anti-Sm precipitlns. 
to the same peptide on the solid phase. In the absence of ex- 
tensive absorption, these antisera could not be used, there- 
fore, for their original purpose. This observation led us to 
suspect that an autoimmune response may have been gener- 
ated against components ofSm B/B' in addition to the anti- 
genic epitopes defined by the PPPGMRPP and PPPGIRGP 
peptides. 
Assessment of binding using the 233 octapeptides of Sm 
B/B' has shown that in addition to binding PPPGMRPP and 
PPPGIR.GP,  sera from rabbits  immunized with these pep- 
tides bad expanded their immune responses  to bind other 
octapeptides of Sm B/B'. An example of the maturation of 
the binding to Sm B/B' octapeptides is shown in Fig. 2 from 
rabbit #463  which was immunized with PPPGMRPP. 
The serum used to produce the binding shown in Fig. 2 
C  was  absorbed to a column with a MAP  TM  PPPGMR.PP 
ligand. This absorption removed the binding activity to the 
three PPPGMRPP and the one PPPGIRGP octapeptides found 
in Sm B/B' whereas the binding remained essentially unaltered 
to the other seven of the 11 groups of octapeptides with the 
greatest binding by this serum (refer to inset, Fig. 2 C). Ab- 
sorption of anti-PPPGMRPP binding antibodies specifically 
reduces the anti-Sm activity (per milligram IgG) in this rabbit 
serum by 34%, as measured in an ELISA using purified Sm 
antigen. 
Many of the same octapeptides of Sm B/B' are bound by 
serum from the rabbit shown in Fig.  2 are also bound by 
serum from the human serum with an anti-Sm B/B' responses 
shown in Fig. 1. This result is consistent with the hypothesis 
that PPPGMRPP immunization had induced Sm B/B' au- 
toimmunity. Subsequent experiments, including character- 
ization of the autoimmune response of animals similarly im- 
munized with these and control immunogens, were performed 
to test the validity of this particular interpretation of the un- 
expected initial results. 
Other rabbits were immunized with PPPGMRPP. In ad- 
dition, control peptide, MAP  TM backbone and sham immu- 
nizations were performed to explore the specificity of the ob- 
served response. A control peptide was chosen from a region 
of Sm B/B' which was known to be less commonly autoan- 
tigenic in human SLE sera with anti-Sm precipitins  (Sm B/B' 
168) and from nonautoantigenic and autoantigenic regions 
of human 60-kD Ro (Ro 274, Ro 413, Ro 480, and Ro 500). 
All 15 rabbits immunized with PPPGMRPP or PPPGIR.GP 
bound the MAP  TM PPPGMRGP peptide in the solid phase, 
whereas none of the 14 control immunized rabbits bound 
this peptide. 
Also, the average binding of the serum from eight rabbits, 
followed for at least 160 d of the immunization Schedule A, 
shows that they also tend to bind the same octapeptides from 
Sm B/B' as bound by a cohort of 14 patients with anti-Sm 
and whose serum bind Sm B/B' in Western blot (Fig.  3). 
16  of the  18  Sm B/B'  octapeptide groups bound by the 
PPPGMRPP or PPPGIRGP immunized rabbit sera are also 
bound by the human anti-Sm sera evaluated (odds ratio = 13.3, 
95% confidence interval 11.6 to 15.0, X  2 =  11.27, degrees 
of freedom  =  1, p  <0.0001). 
That rabbits immunized with PPPGMRPP or PPPGIR.GP 
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other observations.  14  of the  15  rabbits immunized with 
PPPGMRPP or PPPGIRGP bound the purified nRNP and 
Sm antigens in solid-phase assays whereas none of the con- 
trol immunized animals developed this specificity. The same 
14 of 15 PPPGMRPP or PPPGIRGP immunized animals de- 
veloped antibodies against other groups of octapeptides from 
Sm B/B'. One of these patterns of binding to Sm B/B' was 
less complex than the example of rabbit #463 shown (Fig. 
2), whereas others were more complicated, thereby revealing 
the variation that would be expected from an Sm autoantigen- 
driven response. Most of the 11 Sm B/B' regions antigenic 
in humans were also bound by serum from each rabbit with 
an autoimmune response that spreads  among the Sm B/B' 
octapeptides. 
If autoimmunity directed against Sm B/B' had been gener- 
ated  in  these  animals  and  if the  immunization  protocols 
generate an animal model with some of the features of im- 
mune dysregulation found in human SLE, then spliceosomal 
autoimmunity beyond Sm B/B' would be expected. There- 
fore, a subset of the experimental and control animals was 
evaluated for binding to the 1,202 overlapping octapeptides 
from the autoantigenic proteins of the spliceosome, which 
include Sm B/B', Sm D, nRNP 70K, nRNP A, and nRNP 
C. None of these octapeptides was bound by sera from the 
three rabbits immunized with R,o 480, the four Freund's ad- 
juvant sham-immunized control animals,  nor the eight avail- 
able preimmune PPPGMRPP or PPPGIRGP animals. In con- 
trast, all 13 of the PPPGMRPP immunized animals bound 
octapeptides from at least one other spliceosomal protein be- 
yond Sm B/B'.  12 of the 13 sera bound octapeptides from 
Sm D and from nRNP 70K. All 13 bound octapeptides from 
Sm C. 11 of the 13 bound octapeptides from nRNP A. Vari- 
ation within limits is found between animals with regard 
to the particular octapeptides bound, analogous to findings 
in humans (5,  16).  Between 19 and 87 groups of octapep- 
tides from the spliceosome were bound by sera from the 13 
animals immunized with PPPGMRPP and assayed for binding 
to the  1,202  octapeptides from the spliceosome. 
As  an  additional  control,  four  of the  PPPGMRPP  or 
PPPGIRGP immunized animals were evaluated for binding 
to the 531 octapeptides from 60-kD Ro. None of the 60-kD 
Ro octapeptides was bound by sera from these animals, de- 
spite their extensive binding to the spliceosomal octapeptides. 
Two  of the  animals  immunized  with  PPPGMRPP  or 
PPPGIRGP were followed for over a year, respectively, rabbits 
#462 and #465. Both of these long-term survivors have de- 
veloped such high titers of anti-Sm antibodies that their later 
sera form precipitins in Ouchterlony immunodiffusion with 
Sm antigen (Fig.  4). This finding was absent in sera from 
control rabbits immunized with Freund's adjuvant alone, in 
rabbits immunized with peptides from the Ro autoantigen 
(Ro 274, Ro 500, Ro 413,  and Ro 480), or in a rabbit im- 
munized with a less antigenic octapeptide of Sm B/B' (Sm 
B/B'  168). 
Rabbits immunized with the PPPGMRPP and PPPGIRGP 
peptides  also  immunoprecipitate the  human  U  R.NAs  as- 
sociated with the Sm and nRNP proteins (Fig.  5). U1, U2, 
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Figure  4.  Oiichterlony im- 
munodiffusion of PPPGMRPP, 
PPPGIRGP, and control  peptide 
immunized rabbits. Antigen (calf 
thymus extract) is in the center 
well. An anti-Ro, anti-Sm, and 
anti-nRNP precipitin  positive  hu- 
man SLE serum (1) is in the top 
well. Clockwise  from this posi- 
tion is a  postimmunization  serum 
from rabbit #462 (2), an  anti- 
nRNP  precipitin positive SLE 
serum (3), a preimmune serum 
from rabbit #462 (4), an anti-Sm 
precipitin  positive  SLE serum (5), and finally  another  sample  of the postim- 
munization serum from rabbit #462 (6). Immunized  rabbit sera was col- 
lected 16 wk into the immunization  protocol.  Lines  of identity  with anti- 
Sm and anti-nRNP have developed  in the serum of rabbit #462 during 
immunization. 
U4, U5, and U6 form significant bands with the rabbit anti- 
bodies. Rabbit preimmune sera and a rabbit sham immunized 
with Freund's adjuvant alone do not immunoprecipitate any 
of the U  RNAs. 
Rabbits immunized with the PPPGMRPP or PPPGIRGP 
peptides develop high titer antinuclear antibodies. Rabbit #462 
developed antinuclear antibodies to  a titer of 1:1028.  This 
level of autoantibodies remained constant even without ad- 
ditional peptide boosting. Rabbits #463 and #465 also devel- 
oped antinuclear antibodies with a titer of 1:360. All of these 
immunized rabbit sera have antibodies with a nuclear speckled 
pattern,  consistent with the presence of either anti-Sm or 
Figure 5.  RNA immunoprecipitation  from  HeLa  cell  extracts  by serum 
from PPPGMRPP and PPPGIRGP immunized rabbits. (Lane 1  ) Im- 
munoprecitation of U1, U2, U4/U6, and U5 RNAs by an anti-Sm and 
anti-nRNP precipitin  positive  human serum (also shown  in Fig. 1 D) and 
serves as a positive  control. (Lane 2) Immunoprecipitation  of U1, U2, 
U4/U6, and U5 by serum from rabbit #462 160 d after immunization 
with PPPGMRPP. (Lanes 3 and 4) Immunoprecipitation  of U1, U2, 
U4/U6, and U5 by rabbits #463 and #464, respectively.  These  sera were 
collected 72 d after immunization. Rabbit #465 serum (collected  160 d 
after immunization) also immunoprecipitates  U1, U2, U4/U6, and U5 
and is presented  in Lane 5. A control serum, presented  in lane 6, does 
not bind any of  the U RNAs. This serum  was collected  183 d after  immu- 
nization with Freund's adjuvant alone. (Lane  7) Immunoprecipitation  of 
U1, U2, U4/U6, and U5 by another anti-Sm and anti-nRNP precipitin 
positive human serum is again shown and serves  as an additional human 
control. Figure 6.  Antinuclear antibodies and anti-dsDNA antibodies found in PPPGMRPP and PPPGIRGP immunized rabbit sera. (A) Antinuclear fluores- 
cence pattern on HEp-2 cells by a 1:1080 dilution of serum from rabbit #462  collected  181 d after primary immunization. Background binding of 
the preimmune serum from this rabbit is shown as an inlay on the right. This preimmune serum is diluted at  1:360 and was exposed  six times as 
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animals, serum from an animal immunized with a less anti- 
genic region of Sm B/B', and sera from the sham-immunized 
animals were all negative for antinuclear antibodies. 
Two PPPGMRPP or PPPGIRGP octapeptide immunized 
rabbits also developed antibodies to double-stranded DNA. 
Sera from rabbit #462 reacted strongly with the kinetoplast 
of Crithidia  luciliae at a dilution of 1:270 (Fig. 6 B) whereas 
rabbit #465  is positive at 1:30. Preimmune sera from these 
rabbits,  sera from animals immunized with Sm B/B' 168, 
Ro 500,  and Ro 413, MAP  TM, and Freund's adjuvant alone 
were all negative for antibodies to native DNA. 
Sera from some of the immunized rabbits were also evalu- 
ated for antigen binding by Western blot analysis against HeLa 
cell extract and Sm/nRNP antigens (Fig. 7). After immuni- 
zation serum from rabbit #462 binds the appropriate molec- 
ular weight proteins in Western blot for nRNP 70K, nRNP 
A, nRNP C, Sm B/B', and Sm D antigens. Rabbit #463 (also 
immunized with PPPGMRPP) sera binds the 70K nRNP, 
nRNP C, Sm B/B', and Sm D  proteins. Rabbit #465,  im- 
munized with PPPGIRGP, binds the 70K nRNP, nRNP A, 
nRNP C, Sm B/B', and Sm D proteins and serum from rabbit 
#464 (which died early in the immunization protocol) bind 
only the nRNP C, Sm B/B', and Sm D proteins. Preimmune 
sera from these animals did not bind any proteins in Western 
blot. Rabbits immunized with MAP  TM, Freund's adjuvant, 
Ro 500, or Ro 413 did not bind these proteins. The sera from 
rabbits immunized with peptides from autoantigenic regions 
of 60-kD  Ro, however,  strongly bound to 60-kD Ro and 
to octapeptides derived from 60-kD  Ro (data  not shown; 
Scofield, R. H., J. A. James, and J.  B. Harley, manuscript 
in preparation). 
Anti-Sm precipitins are relatively specific for and useful 
in the diagnosis of SLE (1). Their presence led us to examine 
the progression of immune maturation and to evaluate these 
animals for the presence  of other features  found in human 
SLE. Rabbit #462 serves as an example and has had an espe- 
cially interesting disease  course  after immunization with 
PPPGMRPP (Fig. 8). In addition to the antispliceosomal  an- 
tibodies (detected by several different methods as presented 
above),  serum from this rabbit had anti-Sm precipitins,  an- 
tinuclear antibodies, and antidouble-stranded DNA antibodies. 
Rabbit  #462  had  substantial  proteinuria  and  mild  renal 
insufficiency  with a creatinine as high as 1.7 mg/dl. The pro- 
teinuria was measured to be 168 mg/kg/d, which is approxi- 
mately the level found in a human with 8 g proteinuria/d. 
Not surprisingly, his albumin decreased to 1.3 g/dl. His serum 
level of creatinine phosphokinase was elevated. The platelet 
count dropped as low as 27,000/#1.  This animal lost hair 
much more rapidly than controls and had lost 2.49  kg or 
39% of its weight. Rabbit #462 clearly satisfies the criteria 
Figure 7.  Western  blot analysis  of PPPGMRPP 
and PPPGIRGP immunized  rabbit sera. (Lane I ) 
Reactivity  ofa postimmune  serum  from  rabbit #462 
with the 70K, nRNP A, nRNP C, Sm B/B', and 
Sm D proteins. (Lane  2) Reactivity  of  rabbit #463, 
which died early  in the immunization  protocol, 
with the 70K nRNP, nRNP C, Sm B/B', and Sm 
D proteins. (Lane  3) Reactivity  of  rabbit #464 with 
nRNP C, Sm B/B', and Sm D. (Lane  4  ) Binding 
of rabbit #465, a long-term  survivor  immunized 
with PPPGIRGP,  with 70K, nRNP A, nRNP C, 
Sm B/B', and Sm D proteins after  immunization. 
(Lane 5) Background  reactivity  of a rabbit sham- 
immunized with Freund's adjuvant  alone. 
for SLE (1)  ordinarily applied to humans by virtue of the 
presence  of a positive ANA,  anti-Sm, anti-DNA, protein- 
uria,  and thrombocytopenia. 
Rabbit #465 (PPPGIRGP), the other long-term survivor, 
has had anti-Sm precipitins, a positive antinuclear antibody 
(1:360),  3 +  proteinuria (with hypoalbuminemia), and sei- 
zures, all consistent with SLE (1). No seizures and no persis- 
tent proteinuria was observed in any of the control animals. 
Three animals died early in the immunization protocol. 
All were immunized with PPPGMRPP or PPPGIRGP. One 
died of bowel obstruction unrelated to SLE autoimmunity. 
Two died before being evaluated for SLE or autoimmunity. 
Both had seizures and among the most complex antispliceo- 
some responses at that point in the immunization protocol, 
as measured by the 66 and 84 groups of spliceosome octapep- 
tides bound. 
Two immunization schedules were applied. Schedule A was 
uniformly successful in inducing antispliceosomal antibody 
by a number of measures.  Schedule B was used in only one 
experimental set. These PPPGMRPP immunized animals ex- 
perienced immunoglobulin spreading much more slowly than 
the others. Since the number of animals immunized was small 
and since a simultaneous comparison was not attempted, no 
firm conclusions can be drawn from these observations. 
Discussion 
These findings not only have important implications for 
understanding SLE, but may also be important for explaining 
the pathogenesis of other humoral autoimmune disorders. 
We have demonstrated that immunity against a single struc- 
ture defined by a peptide may initiate an expanded autoim- 
mune response against the molecule from which the peptide 
has been derived.  While the rules defining which peptides 
are capable of inducing this response  are not yet apparent, 
long as A. (B) Serum at a dilution of 1:270 from rabbit #462 collected 155 d after primary  immunization  which binds strongly  to the kinetoplast 
of C. luciliae. Anti-dsDNA antibodies were first found  in this rabbit #462 on day 71 after primary  immunization.  Again, background  reactivity  of 
the preimmune  serum from this rabbit is presented as an inlay  on the right of/~ This control serum is diluted 1:10 and the photograph has been 
exposed eight times as long as the image in the remainder of/~ 
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DAYS AFTER FIRST IMMUNIZATION  RABBIT 
Figure 8.  The development  of autoimmunity  in rabbit #462 after  im- 
munization with PPPGMRPP. Immunizations  are indicated (y) in A. 
Dilutions of sera (1:100) were tested in ELISAs for antibodies  binding  to 
PPPGMRPP and bovine  nuclear  ribonudeoprotein  (nRNP). Serum titers 
of  antibody  binding  to fixed  HEp-2 cells  (ANA) and C.  luciliae kinetoplasts 
(antl-dsDNA) are determined  by immunofluorescence  assay.  The level of 
creatinine, creative phosphokinase, and platelets in the peripheral blood 
and protein in the urine is presented. Proteinuria  is measured  on a semi- 
quantitative  scale  of 0 to 4 +. Anti-Sm  precipitins  by Ouchterlony  immuno- 
diffusion  are present (+) in later sera, but absent in earlier sera (-). The 
average results of normal rabbits are presented  as a point of reference  (￿9 
it is probably important that an antigenic peptide of  the spliceo- 
some was chosen. Immunization with peptides from other 
autoantigens or from an area antigenic in only a few human 
sera from Sm B/B' (Sm B/B' 168) failed to induce the cas- 
cade of events leading to spliceosomal  autoimmunity. Also, 
analogy to the recently demonstrated spreading of T cell au- 
toimmune epitopes (17) is obvious. 
An autoimmune response progressing from one or a few 
structures to a complicated humoral autoimmune response 
is consistent with molecular mimicry theories of autoimmune 
disease (7, 18, 19). Of the known protein sequences, the im- 
munogen used here,  PPPGMR.PP,  is most similar to PPP- 
GRRP from Epstein-Barr nuclear antigen I (EBNA-1) of  EBV 
which is also bound by human sera containing anti-Sm au- 
toantibodies (4). 
If some of the other experimentally induced models of SLE 
(20-24)  are related to the new model presented here,  then 
they must have common features.  Perhaps  SLE autoimmu- 
nity is the result of dysregulation of a paratope-idiotype-anti- 
idiotype network of immune maturation via any one of a 
number of initial immune responses. Whether the paratope, 
idiotype or anti-idiotype acts to trigger the response may be 
relatively immaterial. 
While the immunological details and subsequent disease 
characteristics  may differ, autoimmunity may be a character- 
istic and common consequence of a number of different kinds 
of initiating events. Perhaps most, if not all, optimally chal- 
lenged  immunologically competent  mammalian  immune 
systems  have the potential to develop  SLE autoimmunity. 
For example, BALB/c mice have been immunized with PPP- 
GMRPP or PPPGIRGP. Each of the 10 mice available for 
analysis have developed an antispliceosome autoimmune re- 
sponse (some with concurrent proteinuria) that has been ab- 
sent from control immunized animals (James, J. A., andJ. B. 
Harley, unpublished observations). 
Particular  antibodies,  here  anti-PPPGMRPP  and  anti- 
PPPGIR,GP as well as the B cells that produce them, are there- 
fore likely to be important in the induction of SLE autoim- 
munity. Indeed, these findings strongly support a recently 
advocated  concept postulating a central role for B cells in 
generating autoimmune responses  (25,  26).  In our experi- 
ments, the B cell that binds both PPPGMRPP or PPPGIRGP 
and endogenous spliceosome of the rabbit (which also would 
contain the peptide immunogen) is postulated to have the 
capacity to not only bind the spliceosome, but also to pro- 
cess and present this and other spliceosome-derived  peptides 
to T  cells. With the appropriate immune stimulus, immu- 
noglobulin epitope spreading and autoimmunity evidently 
follow. 
Our findings support the possibility that human SLE is 
accompanied or induced by immune responses  to relatively 
simple antigenic structures.  The development of autoimmune 
disease would appear to be the consequence of immunoregula- 
tory events that, once initiated, progress automatically and 
culminate in a systemic autoimmune disorder.  These results 
also demonstrate the potential for individual autoantibody 
specificities, as well as, for the SLE R.NA-protein autoantigens 
(Sm, nRNP, Ro, and La) to contribute toward pathogenesis 
of disease. 
The extent to which clinical  manifestations observed  in 
our  PPPGMRPP  or  PPPGIRGP  immunized animals  are 
directly attributable to and specific for a SLE autoimmune 
process is not known. The PPPGMRPP or PPPGIRGP im- 
munized rabbits have variably had seizures, proteinuria, throm- 
bocytopenia, and alopecia,  which are all known to be part 
of human SLE. Of course, immunization with Freund's ad- 
juvant is a substantial immune challenge and may account 
for some of these findings. Concluding that these particular 
findings bear more than a superficial resemblance to SLE au- 
toimmunity must await a direct and rigorous description of 
the mechanisms involved. In any case, a new method of gener- 
ating autoimmunity and for observing the subsequent matu- 
ration of the autoimmune response  has been described. 
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